NR4A1 and neoplasm: The tumor growth inhibitory effects of CDIM/NR4A1 antagonists were observed in immune competent mice bearing MC-38 mouse colon cancer cells (Fig. 3) and this was accompanied by modest changes in CD8+ and CD4+ T-cells and Treg cells in TILs and a significant decrease in CD4+/CD8+ ratios (Fig. 4).